Fangzhou Jianke: It is expected that the net profit in 2025 will be about 7 to 10 million yuan, turning losses into profits year on year.

Fangdeng Ark Pharmaceuticals announced on the Hong Kong Stock Exchange that, based on the preliminary review of the unaudited comprehensive management accounts of the Company for the year ended December 31, 2025, it is expected that the Company's revenue during the reporting period will range from approximately RMB 3.5 billion to RMB 3.55 billion, representing a year-on-year growth of approximately 30%. It is expected that the Company will record a net profit of approximately RMB 7 million to RMB 10 million during the reporting period, a significant turnaround from the pre-tax net loss of RMB 855 million in the same period last year. The expected increase in revenue is mainly due to the continuous growth of the Company's consumer-facing business segments.